U.S. stock markets have retreated in January after a sharp rally in 2023. The euphoria surrounding technology stocks evaporated primarily owing to the uncertainty regarding the time when the Fed would initiate the first cut in the benchmark interest rate.Recently, a few key Fed FOMC members said that although they believe that the rate hike regime is over, they are yet to be convinced that the economic condition is conducive enough for an immediate rate cut.Hotter-than-expected nonfarm payrolls and consumer ...

Company Participants Hadar Levy - Chief Executive Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Operator Brainsway Ltd (NASDAQ:BWAY) Q3 2023 Earnings Conference Call November 15, 2023 8:30 AM ET Brian Ritchie - Investor Relations, LifeSci Advisors Ido Marom - Chief Financial Officer Jayson Bedford - Raymond James Carl Byrnes - Northland Capital Markets Boobalan Pachaiyappan - H.C. Wainwright Good day and welcome to BrainsWay Third Quarter 2023 Earnings Call. At this time all partic ...

There are no further questions in the queue at this time. I will turn the call back over to Hadar for any closing remarks. Hadar Levy I would like to thank all of the investors, analysts and other participants for their interest in BrainsWay. With that, please enjoy the rest of your day. Thank you. Operator Thank you, ladies and gentlemen. This concludes your teleconference. Please disconnect your lines. Okay. Got it. And then Ido on the financial side, could you just give us a sense, you talked about a red ...

BrainsWay Ltd. (NASDAQ:BWAY) Q1 2023 Earnings Call May 17, 2023 8:30 AM ET Brian Ritchie - Investor Relations, LifeSci Advisors Scott Areglado - Senior Vice President and Chief Financial Officer Jeffery Cohen - Ladenburg Thalmann Boobalan Pachaiyappan - H.C. Wainwright I would now like to turn the conference over to your host, Brian Ritchie with LifeSci Advisors. Thank you. You may begin. The format for today's call will be a discussion of recent trends and business updates from Hadar, followed by a detaile ...

Revenue and Financial Performance - Revenues are expected to increase due to the expansion of the Deep TMS system marketing for MDD, OCD, and smoking addiction, with a decrease in the gap between operating expenses and revenues compared to 2022 levels [930]. - Net cash used in operating activities was $9.8 million for the year ended December 31, 2022, a decrease of $10.7 million compared to a net cash provided of $0.9 million in 2021, primarily due to higher losses and changes in working capital [931]. - The company anticipates that the trend of increased reimbursement coverage for Deep TMS could positively impact revenues, income from continuing operations, and profitability [955]. Government Grants and Royalties - As of December 31, 2022, the company received approximately $13.4 million in government grants, with $4.4 million paid in royalties, leaving outstanding royalties of up to $11.6 million [932]. - The company has engaged in research and licensing agreements with Yeda, which include royalties ranging from 1.6% to 5% for certain products [950]. Coverage and Market Expansion - Over 90 million covered lives are eligible for reimbursement for Deep TMS treatment of OCD as of March 2023, with positive coverage decisions from several major insurers [955]. - The company is actively working to facilitate increased coverage for OCD treatment by more payors, including both commercial and governmental [955]. Leadership and Organizational Changes - A leadership transition occurred in early 2023, with Mr. Ami Boehm appointed as Chairman and Mr. Hadar Levy as the new CEO [956]. - The company has seen a trend of high workforce volatility, affecting recruitment and retention of sales professionals [954]. Intellectual Property and Technology - The company has a total of 34 issued U.S. patents and 51 issued patents in other jurisdictions related to Deep TMS technology, with various expiration dates ranging from 2021 to 2039 [937]. - The company has acquired additional patents related to multichannel stimulation, which are expected to broaden the capabilities of its developing multichannel stimulator [968]. - The core technology for Deep TMS is exclusively licensed for worldwide commercialization, with rights owned by the DHHS and licensed through the PHS [969]. - The company has achieved all milestones under the PHS license agreement, which is valid until the last licensed patent expires [972]. - The company may rely on trade secrets and know-how to protect its technology, although such protection can be challenging [975]. Supply Chain and Inventory Management - The company has seen a significant rise in the price of electronic components due to supply and demand factors, leading to increased inventory levels to meet future demand [977]. - The lead time for receiving electronic components has increased significantly amid the global supply chain crisis, impacting ongoing supply capabilities [977]. Financial Controls and Ethics - The audit committee is responsible for overseeing the quality and integrity of the company's accounting, auditing, and reporting practices [773]. - The company has adopted a code of ethics applicable to its principal executive and financial officers, which is available on its website [771]. - The company has established internal controls over financial reporting to ensure reliability and compliance with generally accepted accounting principles [769].

BrainsWay Ltd. (NASDAQ:BWAY) Q4 2022 Earnings Conference Call March 15, 2023 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Hadar Levy - Chief Executive Officer Scott Areglado - Senior Vice President and Chief Financial Officer Conference Call Participants Steve Lichtman - Oppenheimer Jeffrey Cohen - Ladenburg Thalmann Boobalan Pachaiyappan - H. C. Wainwright Operator Greetings and welcome to the BrainsWay Fourth Quarter and Full-Year 2022 Earnings Call. At this time, a ...

BrainsWay Ltd. (NASDAQ:BWAY) Q3 2022 Results Earnings Conference Call November 16, 2022 8:30 AM ET Company Participants Bob Yedid - Investor Relations, LifeSci Advisors Christopher von Jako - President and Chief Executive Officer Scott Areglado - Chief Financial Officer Conference Call Participants Steven Lichtman - Oppenheimer & Co. Inc. Jeffery Cohen - Ladenburg Thalmann Jayson Bedford - Raymond James & Associates, Inc. Boobalan Pachaiyappan - H.C. Wainwright & Co. Jason Wittes - Loop Capital Operator Lad ...

BrainsWay Ltd. (NASDAQ:BWAY) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET Company Participants Bob Yedid – LifeSci Advisors Christopher von Jako – President and Chief Executive Officer Scott Areglado – Chief Financial Officer Conference Call Participants Steve Lichtman – Oppenheimer Jayson Bedford – Raymond James Jeffery Cohen – Ladenburg Thalmann Raghuram Selvaraju – H.C. Wainwright Jason Wittes – Loop Capital Operator Good morning, and welcome to BrainsWay Second Quarter 2022 Earnings Confe ...

Elevating Mental Health Treatment May 2022 Nasdaq/TASE: BWAY Disclaimer Safe Harbor and Non-GAAP Financial Measures This presentation does not constitute an offer or invitation to sell or issue, or any solicitation of an offer to subscribe for or acquire any of the Company's securities or to participate in any investment in the Company. No representation or warranty is made to the accuracy or completeness of this presentation. You must make your own investigation and assessment of the matters contained here ...

BrainsWay Ltd. (NASDAQ:BWAY) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Bob Yedid – LifeSci Advisors Chris von Jako – President and Chief Executive Officer Scott Areglado – Chief Financial Officer Conference Call Participants Jeffery Cohen – Ladenburg Thalmann Jayson Bedford – Raymond James Steven Lichtman – Oppenheimer Jason Wittes – Loop Capital Carl Byrnes – Northland Capital Markets Operator Greetings, and welcome to BrainsWay First Quarter 2022 Earnings Conference Cal ...